Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) ...

Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

All in all, there is some evidence to suggest that the occasional properly processed juice shot is beneficial, and little ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Oral ivarmacitinib was effective for the treatment of moderate to severe atopic dermatitis in adults and adolescents, ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

The HHS will require all new vaccines to undergo placebo-controlled trials, likely slowing down approvals and decreasing access.

Johnson & Johnson said on Friday its experimental psoriasis drug met the main goal of a late-stage study, as the once-daily ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...